[1] [1] JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2007［J］. CA: A Cancer Journal for Clinicians, 2007, 57(1): 43-66.

[2] [2] ZHENG Z, WEN Y, NIE K, et al. Construction of a 13-microR-NA-based signature and prognostic nomogram for predicting over-all survival in patients with hepatocellular carcinoma［J］. Hepatol-ogy Research, 2020, 50(10): 1151-1163.

[3] [3] BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 389(10064): 56-66.

[4] [4] RAVELLI A, REUBEN J M, LANZA F, et al. Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity［J］. Expert Review of Anticancer Therapy, 2015, 15(6): 689-702.

[5] [5] LIU H. Pan-cancer profiles of the cuproptosis gene set［J］. Ameri-can Journal of Cancer Research, 2022, 12(8): 4074-4081.

[6] [6] KAMIYA T. Copper in the tumor microenvironment and tumor metastasis［J］. Journal of Clinical Biochemistry and Nutrition, 2022, 71(1): 22-28.

[7] [7] KESWANI T, MITRA S, BHATTACHARYYA A. Copper-induced immunotoxicity involves cell cycle arrest and cell death in the liver［J］. Environ Toxicol, 2015, 30(4): 411-421.

[8] [8] TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins［J］. Science, 2022, 375(6586): 1254-1261.

[9] [9] WEI S, DU M, JIANG Z, et al. Long noncoding RNAs in regulat-ing adipogenesis: new RNAs shed lights on obesity［J］. Cellular and Molecular Life Sciences, 2016, 73(10): 2079-2087.

[10] [10] MA Y, ZHANG J, WEN L, et al. Membrane-lipid associated ln-cRNA: a new regulator in cancer signaling［J］. Cancer Letters, 2018, 419: 27-29.

[11] [11] GAI C, LIU C, WU X, et al. MT1DP loaded by folate-modified li-posomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells［J］. Cell Death Disease, 2020, 11(9): 751.

[12] [12] WANG C Z, YAN GX, DONG DS, et al. LncRNA-ATB pro-motes autophagy by activating Yes-associated protein and induc-ing autophagy-related protein 5 expression in hepatocellular carcinoma［J］. World Journal of Gastroenterology, 2019, 25(35): 5310-5322.

[13] [13] YANG L, YU J, TAO L, et al. Cuproptosis-related LncRNA are biomarkers of prognosis and immune microenvironment in head and neck squamous cell carcinoma［J］. Frontiers in Genetics, 2022, 13: 947551.

[14] [14] XU Z, PENG B, LIANG Q, et al. Construction of a ferroptosis-re-lated nine-lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma［J］. Frontiers in Immunol-ogy, 2021, 12: 719175.

[15] [15] JIANG P, GU S, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response［J］. Nature Medicine, 2018, 24(10): 1550-1558.

[16] [16] ASHBURNER M, BALL C A, BLAKE J A, et al. Gene ontology: tool for the unification of biology［J］. Nature Genetics, 2000, 25(1): 25-29.

[17] [17] KANEHISA M, GOTO S. KEGG: Kyoto encyclopedia of genes and genomes［J］. Nucleic Acids Research, 2000, 28(1): 27-30.

[18] [18] GEELEHER P, COX N, HUANG R S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels［J］. PLoS One, 2014, 9(9): e107468.

[19] [19] GUO Y, WANG R, LI J, et al. Comprehensive analysis of m6A RNA methylation regulators and the immune microenvironment to aid immunotherapy in pancreatic cancer［J］. Frontiers in Immu-nology, 2021, 12: 769425.

[20] [20] LEE S K, JANG J W, NAM H, et al. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation［J］. Hepatology International, 2021, 15(1): 137-145.

[21] [21] YU J I, LEE S J, LEE J, et al. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carci-noma［J］. Cancer Medicine, 2019, 8(16): 6986-6994.

[22] [22] SHIMOSE S, HIRAOKA A, NAKANO M, et al. First-line sorafenib sequential therapy and liver disease etiology for un-resectable hepatocellular carcinoma using inverse probability weighting: a multicenter retrospective study［J］ . Cancer Medicine, 2021, 10(23): 8530-8541.

[23] [23] LEI M, DU X, LI X, et al. LINC00665 regulates hepatocellular carcinoma by modulating mRNA via the m6A enzyme［J］ . Open Life Sciences, 2022, 17(1): 71-80.

[24] [24] XU Y, LIU S Y, ZENG L, et al. An enzyme-engineered nonporous copper (I) coordination polymer nanoplatform for cuproptosis-based synergistic cancer therapy［J］ . Advanced Materials, 2022, 34(43): e2204733.

[25] [25] FENG Y, ZENG J W, MA Q, et al. Serum copper and zinc levels in breast cancer: a meta-analysis［J］ . Journal of Trace Elements in Medicine and Biology, 2020, 62: 126629.

[26] [26] WANG W, WANG X, LUO J, et al. Serum copper level and the copper-to-zinc ratio could be useful in the prediction of lung can-cer and its prognosis: a case-control study in northeast China［J］ . Nutrition and Cancer, 2021, 73(10): 1908-1915.

[27] [27] KHOSHDEL Z, NAGHIBALHOSSAINI F, ABDOLLAHI K, et al. Serum copper and zinc levels among iranian colorectal cancer patients［J］ . Biological Trace Element Research, 2016, 170(2): 294-299.

[28] [28] SHAS, SI L, WU X, et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer［J］ . Frontiers in Im-munology, 2022, 13: 922780.

[29] [29] TANG X, JIANG F, WANG X, et al. Identification of the ferropto-Ophthalmology, 2018, 136(7): 820-823.